Gracell initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Emily Bodnar initiated coverage of Gracell Biotechnologies with a Buy rating and $6 price target. Gracell is a cell therapy company developing autologous and allogeneic CAR-T therapies for hematologic malignancies and solid tumors with its proprietary technology platforms, Bodnar tells investors in a research note.